In 2019, UPMC and China-based multi-national conglomerate Wanda Group signed a far-reaching strategic cooperation agreement to jointly build and operate five world-class hospitals in China. UPMC will provide expertise in hospital design, operations, and management best practices that will meet the highest international quality standards. By collaborating in the development of these hospitals, both UPMC and Wanda Group are engaging in a valuable exchange of knowledge and expertise, while bringing patients the highest quality medical care as close to home as possible.
Wanda Group is one of the world's largest real estate, film, children’s entertainment, sports, and tourism companies. Its expansion into health care is guided by China’s national “Healthy China 2030” policy, which encourages private investments to supplement the public hospital system.
In 2014, UPMC and Xiangya Hospital, Central South University elevated their decade-long research and clinical collaboration by partnering to develop a world-class International Medical Center.
As part of this advisory agreement, UPMC will provide Xiangya Hospital with technical and management consulting services, including:
UPMC will provide medical and administrative oversight of all services in the International Medical Center, and a small number of UPMC staff will be located on-site to perform consultative work throughout the duration of the agreement.
In 2018, UPMC entered into an agreement with Tahoe Hospital Management Co. Ltd. to assist in the planning and operation of an expanded cancer center within an existing private hospital in Beijing. From facility planning to clinical protocols, UPMC will advise Tahoe on all aspects of operating an advanced cancer treatment center, which will include:
Drawing on decades of expertise at UPMC Hillman Cancer Center, UPMC will collaborate with Tahoe to meet the growing demand for high-quality cancer care in China, and to enhance its existing cancer program inside the Beijing Yuho Rehabilitation Hospital.
In 2011, UPMC entered into an agreement with KingMed Diagnostics, the largest independent medical diagnostic laboratory in China.
Through this partnership, UPMC’s Department of Pathology provides second opinions for high-acuity anatomical pathology cases. Using equipment that scans glass pathology slides and stores and transmits the images electronically, KingMed receives second opinions on patient diagnoses from our UPMC pathologists through a secure, web-based telepathology portal.
The agreement provides KingMed's patients with rapid access to UPMC’s expert pathologists, thereby helping to ensure accurate diagnoses of complex diseases.
UPMC’s collaboration with KingMed also includes training for pathologists from China in UPMC’s Pittsburgh facilities and joint academic meetings as part of ongoing medical education in China.
UPMC is a founding member of the U.S.-China Healthcare Cooperation Program (HCP), a public-private partnership of 18 companies and 10 nonprofit organizations.
Supported by United States governmental agencies and the Chinese ministries of health and commerce, HCP is a vehicle for the two countries to work together in:
HCP supports projects in: